SDZ WAG 994Potent, selective A1 agonist CAS# 130714-47-5 |
- MDL-29951
Catalog No.:BCC4059
CAS No.:130798-51-5
- Ro 25-6981 Maleate
Catalog No.:BCC4159
CAS No.:1312991-76-6
- Ro 25-6981
Catalog No.:BCC4158
CAS No.:169274-78-6
- SDZ 220-581 hydrochloride
Catalog No.:BCC4157
CAS No.:179411-93-9
- (+)-MK 801
Catalog No.:BCC1288
CAS No.:70449-94-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 130714-47-5 | SDF | Download SDF |
| PubChem ID | 164305 | Appearance | Powder |
| Formula | C17H25N5O4 | M.Wt | 363.41 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in 1.1eq. NaOH and to 100 mM in DMSO | ||
| Chemical Name | (2R,3R,4R,5R)-5-[6-(cyclohexylamino)purin-9-yl]-2-(hydroxymethyl)-4-methoxyoxolan-3-ol | ||
| SMILES | COC1C(C(OC1N2C=NC3=C2N=CN=C3NC4CCCCC4)CO)O | ||
| Standard InChIKey | JAKAFSGZUXCHLF-LSCFUAHRSA-N | ||
| Standard InChI | InChI=1S/C17H25N5O4/c1-25-14-13(24)11(7-23)26-17(14)22-9-20-12-15(18-8-19-16(12)22)21-10-5-3-2-4-6-10/h8-11,13-14,17,23-24H,2-7H2,1H3,(H,18,19,21)/t11-,13-,14-,17-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent and selective A1 adenosine receptor agonist (Ki values are 23, > 10000 and 25000 nM for A1, A2A and A2B receptors respectively). Causes a sustained fall in blood pressure and heart rate in spontaneous hypertensive rats and inhibits adenosine deaminase-stimulated lipolysis in rat adipocytes (Ki = 8 nM). |
SDZ WAG 994 Dilution Calculator
SDZ WAG 994 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.7517 mL | 13.7586 mL | 27.5171 mL | 55.0343 mL | 68.7928 mL |
| 5 mM | 0.5503 mL | 2.7517 mL | 5.5034 mL | 11.0069 mL | 13.7586 mL |
| 10 mM | 0.2752 mL | 1.3759 mL | 2.7517 mL | 5.5034 mL | 6.8793 mL |
| 50 mM | 0.055 mL | 0.2752 mL | 0.5503 mL | 1.1007 mL | 1.3759 mL |
| 100 mM | 0.0275 mL | 0.1376 mL | 0.2752 mL | 0.5503 mL | 0.6879 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- (R)-(+)-Propranolol hydrochloride
Catalog No.:BCC6810
CAS No.:13071-11-9
- Dorzolamide HCl
Catalog No.:BCC2311
CAS No.:130693-82-2
- RP 001 hydrochloride
Catalog No.:BCC7905
CAS No.:1306761-53-4
- Ozanimod (RPC1063)
Catalog No.:BCC6533
CAS No.:1306760-87-1
- PD123319
Catalog No.:BCC5010
CAS No.:130663-39-7
- Bindarit
Catalog No.:BCC4965
CAS No.:130641-38-2
- N-(2-Hydroxyethyl)-3-(4-nitrophenyl)propylamine
Catalog No.:BCC9053
CAS No.:130634-09-2
- (R)-(+)-Corypalmine
Catalog No.:BCN2289
CAS No.:13063-54-2
- Nitidine chloride
Catalog No.:BCN4957
CAS No.:13063-04-2
- Yangambin
Catalog No.:BCN6706
CAS No.:13060-14-5
- alpha-Terthienylmethanol
Catalog No.:BCN6161
CAS No.:13059-93-3
- Mogroside III
Catalog No.:BCN3167
CAS No.:130567-83-8
- FR 122047 hydrochloride
Catalog No.:BCC7092
CAS No.:130717-51-0
- Decloxizine dihydrochloride
Catalog No.:BCC5549
CAS No.:13073-96-6
- m-CPP hydrochloride
Catalog No.:BCC5680
CAS No.:13078-15-4
- 6-O-benzoylgomisin O
Catalog No.:BCN3092
CAS No.:130783-32-3
- MDL-29951
Catalog No.:BCC4059
CAS No.:130798-51-5
- Sipatrigine
Catalog No.:BCC7847
CAS No.:130800-90-7
- Pseudolarifuroic acid
Catalog No.:BCN8048
CAS No.:130825-79-5
- 7-Oxohinokinin
Catalog No.:BCN6162
CAS No.:130837-92-2
- Scoparinol
Catalog No.:BCN6163
CAS No.:130838-00-5
- Decursinol angelate
Catalog No.:BCC9222
CAS No.:130848-06-5
- ent-kaurane-3,16,17-triol
Catalog No.:BCN6164
CAS No.:130855-22-0
- 1beta,10beta-Epoxydehydroleucodin
Catalog No.:BCN7331
CAS No.:130858-00-3
A tandem solid phase extraction, reversed-phase HPLC method for determining SDZ WAG 994 in dog, monkey and rat blood.[Pubmed:9172100]
J Pharm Biomed Anal. 1997 Mar;15(6):749-58.
The development and validation of a sensitive and specific HPLC method for SDZ WAG 994 (I) in dog, monkey and rat blood is described. Sample preparation entailed double solid phase extraction (SPE) of I and the internal standard from 0.5 ml of animal blood using a phenyl and propyl sulfonic acid cation exchange column, sequentially. Chromatographic separation was achieved on a YMC Basic C-8 narrowbore HPLC column and the eluates were detected by UV absorption at 266 nm. The method has a linear response up to at least 1800 ng/ml with a limit of quantification of 1 ng/ml across all species. Analysis of 'blinded' quality control dog and monkey blood samples over 3 or 4 days produced median precisions of 2.89 and 4.77%, and median reproducibilities of 4.86 and 10.9%, respectively. Curve fitting of variability estimates indicated that concentration independent error contributed 3-9% of the total method error for the tandem SPE procedure. Extracted endogenous material from blood matrices, several potential metabolites and cyclohexyladenosine were well resolved from the peaks of interest. The stability of I in dog blood stored at -20 degrees C is at least 6 months. The overall absolute and relative recovery of I using the tandem SPE procedure was 85.5 +/- 5.1% and 96.5 +/- 5.0%, respectively. The ruggedness of the method has been demonstrated by multiple analyses, from several toxicokinetic studies, performed by different analysts using comparable instrumentation.
Adenosine receptors as therapeutic targets.[Pubmed:16518376]
Nat Rev Drug Discov. 2006 Mar;5(3):247-64.
Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world. There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and inflammatory disorders and cancer. After more than three decades of medicinal chemistry research, a considerable number of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clinically evaluated, although none has yet received regulatory approval. However, recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of adenosine receptor modulators considerably closer.
Hypoglycemic and hypotensive effects of 6-cyclohexyl-2'-O-methyl-adenosine, an adenosine A1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia.[Pubmed:9597368]
Diabetes Res Clin Pract. 1998 Jan;39(1):3-9.
Metabolic and cardiovascular effects of 6-cyclohexyl-2'-O-methyl-adenosine (SDZ WAG 994), a selective and orally-active adenosine A1 receptor agonist, were examined in spontaneously hypertensive rats (SHR) with hyperglycemia (SHR-DM). This model was made by the administration of streptozotocin (STZ; 60 mg/kg s.c.) to SHR 2 days after their birth. The serum glucose concentration and systolic/mean blood pressures (MBP) in 18-22-week-old rats were 14.7 +/- 0.8 mmol/1 and 153 +/- 3/124 +/- 3 mmHg in SHR-DM, 13.7 +/- 0.3 mmol/1 and 123 +/- 3/96 +/- 4 mmHg in normotensive with STZ (WKY-DM), 10.3 +/- 0.3 mmol/1 and 165 +/- 1/136 +/- 3 mmHg in non-treated (without STZ) SHR, and 10.0 +/- 0.3 mmol/1 and 115 +/- 3/90 +/- 4 mmHg in non-treated WKY, SDZ WAG 994 at 0.1 mg/kg p.o. lowered the serum glucose concentration, blood pressure and heart rate in SHR-DM. The effects were associated with the decrease in free fatty acid (FFA), triglyceride (TG), phospholipid (PL) and total cholesterol (TC) in serum of both SHR-DM and WKY-DM. On the contrary, the hypoglycemic effect was not found in WKY-DM, although the hypotensive effect was still observed. These data suggest that the risk factors for metabolic and cardiovascular complications in diabetes are reduced by SDZ WAG 994 through activation of adenosine A1 receptors in adipocyte.
